First National Bank of Omaha lowered its stake in Pfizer, Inc. (NYSE:PFE) by 1.5% during the second quarter, Holdings Channel reports. The fund owned 290,935 shares of the biopharmaceutical company’s stock after selling 4,300 shares during the period. First National Bank of Omaha’s holdings in Pfizer were worth $9,773,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Asset Planning Services Ltd. raised its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. raised its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. raised its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in shares of Pfizer during the first quarter valued at about $121,000. Finally, Cascade Investment Advisors Inc. raised its stake in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,200 shares in the last quarter. 70.10% of the stock is owned by institutional investors.

Shares of Pfizer, Inc. (NYSE PFE) traded down 0.51% during trading on Friday, hitting $33.25. The company had a trading volume of 12,928,473 shares. The company has a market capitalization of $198.43 billion, a P/E ratio of 24.32 and a beta of 1.00. The stock’s 50-day moving average price is $33.40 and its 200 day moving average price is $33.31. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.38.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the business earned $0.64 EPS. Pfizer’s revenue was down 1.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.85%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.

TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (NYSE:PFE) Stake Decreased by First National Bank of Omaha” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/12/pfizer-inc-nysepfe-stake-decreased-by-first-national-bank-of-omaha.html.

Several analysts have issued reports on the company. Jefferies Group LLC set a $35.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Morgan Stanley reaffirmed a “neutral” rating and issued a $35.00 target price (down previously from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Berenberg Bank set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 1st. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and cut their target price for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $33.00 target price on shares of Pfizer in a research note on Thursday, April 27th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $37.77.

In related news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.